About Collegium Pharma
Collegium Pharma is a company based in Canton (United States) founded in 2002 by Michael Heffernan.. Collegium Pharma has raised $103 million across 8 funding rounds from investors including TPG, HHS and RA Capital. The company has 357 employees as of December 31, 2024. Collegium Pharma has completed 2 acquisitions, including BioDelivery Sciences International and Ironshore Pharmaceuticals. Collegium Pharma offers products and services including Differentiated Medications. Collegium Pharma operates in a competitive market with competitors including Flexion Therapeutics, Cara Therapeutics, Eliem Therapeutics, Ethypharm and Zogenix, among others.
- Headquarter Canton, United States
- Employees 357 as on 31 Dec, 2024
- Founders Michael Heffernan
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Collegium Pharmaceutical, Inc.
-
Annual Revenue
$631.45 M11.41as on Dec 31, 2024
-
Net Profit
$69.19 M43.68as on Dec 31, 2024
-
EBITDA
$360.47 M11.01as on Dec 31, 2024
-
Total Equity Funding
$103 M (USD)
in 8 rounds
-
Latest Funding Round
$20 M (USD), Post-IPO
Nov 08, 2018
-
Investors
TPG
& 9 more
-
Employee Count
357
as on Dec 31, 2024
-
Investments & Acquisitions
BioDelivery Sciences International
& 1 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Collegium Pharma
Collegium Pharma is a publicly listed company on the NASDAQ with ticker symbol COLL in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Collegium Pharma
Collegium Pharma offers a comprehensive portfolio of products and services, including Differentiated Medications. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Medications addressing serious medical conditions through scientific innovation.
Unlock access to complete
Unlock access to complete
Funding Insights of Collegium Pharma
Collegium Pharma has successfully raised a total of $103M across 8 strategic funding rounds. The most recent funding activity was a Post-IPO round of $20 million completed in November 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 8
- Last Round Post-IPO — $20.0M
-
First Round
First Round
(03 Nov 2006)
- Investors Count 10
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov, 2018 | Amount | Post-IPO - Collegium Pharma | Valuation |
investors |
|
| Mar, 2015 | Amount | Series C - Collegium Pharma | Valuation |
investors |
|
| Sep, 2014 | Amount | Grant - Collegium Pharma | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Collegium Pharma
Collegium Pharma has secured backing from 10 investors, including venture fund and institutional investors. Prominent investors backing the company include TPG, HHS and RA Capital. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Fund of funds focused on pre-seed and seed-stage companies
|
Founded Year | Domain | Location | |
|
Early-stage and late-stage biotech and finance companies are funded.
|
Founded Year | Domain | Location | |
|
Private equity firm focused on life science sector
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Collegium Pharma
Collegium Pharma has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include BioDelivery Sciences International and Ironshore Pharmaceuticals. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Drug delivery technology and ADHD therapeutics are developed.
|
2008 | ||||
|
Specialty pharmaceutical solutions are developed for pain management and addiction.
|
1997 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - Collegium Pharma
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Collegium Pharma Comparisons
Competitors of Collegium Pharma
Collegium Pharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Flexion Therapeutics, Cara Therapeutics, Eliem Therapeutics, Ethypharm and Zogenix, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Developer of therapies for the treatment of musculoskeletal disorders
|
|
| domain | founded_year | HQ Location |
Developer of therapeutics for pain relief and inflammatory diseases
|
|
| domain | founded_year | HQ Location |
Develops antibody-based treatments for autoimmune and inflammatory disorders.
|
|
| domain | founded_year | HQ Location |
Therapies for pain and addiction treatment are developed.
|
|
| domain | founded_year | HQ Location |
Drug delivery systems for CNS disorders and pain are developed.
|
|
| domain | founded_year | HQ Location |
Reformulated injectables for chemotherapy side effects and pain are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Collegium Pharma
Frequently Asked Questions about Collegium Pharma
When was Collegium Pharma founded?
Collegium Pharma was founded in 2002 and raised its 1st funding round 4 years after it was founded.
Where is Collegium Pharma located?
Collegium Pharma is headquartered in Canton, United States. It is registered at Canton, Ohio, United States.
Who is the current CEO of Collegium Pharma?
Michael Heffernan is the current CEO of Collegium Pharma. They have also founded this company.
Is Collegium Pharma a funded company?
Collegium Pharma is a funded company, having raised a total of $103M across 8 funding rounds to date. The company's 1st funding round was a Grant of $472.81K, raised on Nov 03, 2006.
How many employees does Collegium Pharma have?
As of Dec 31, 2024, the latest employee count at Collegium Pharma is 357.
What is the annual revenue of Collegium Pharma?
Annual revenue of Collegium Pharma is $631.45M as on Dec 31, 2024.
What does Collegium Pharma do?
Therapeutics for chronic pain management are developed by Collegium Pharmaceutical, which was founded in 2002 and is based in Canton, United States. The proprietary DETERx platform is used to combine active ingredients with fatty acids and waxes, forming microsphere capsules with extended-release and abuse-deterrent features. Xtampza ER serves as the flagship product, delivering extended-release oxycodone. Formulations for oxymorphone, hydrocodone, morphine, and methylphenidate are also produced.
Who are the top competitors of Collegium Pharma?
Collegium Pharma's top competitors include Flexion Therapeutics, Cara Therapeutics and Trevena.
What products or services does Collegium Pharma offer?
Collegium Pharma offers Differentiated Medications.
Is Collegium Pharma publicly traded?
Yes, Collegium Pharma is publicly traded on NASDAQ under the ticker symbol COLL.
How many acquisitions has Collegium Pharma made?
Collegium Pharma has made 2 acquisitions, including BioDelivery Sciences International, and Ironshore Pharmaceuticals.
Who are Collegium Pharma's investors?
Collegium Pharma has 10 investors. Key investors include TPG, HHS, RA Capital, Frazier Healthcare Partners, and Westfield Capital.
What is Collegium Pharma's ticker symbol?
The ticker symbol of Collegium Pharma is COLL on NASDAQ.